cytarabine + daunorubicin: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
cytarabine + daunorubicin: clinical details
Prescribing considerations
- Confirm the exact liposomal product before prescribing and administration; it is not interchangeable with conventional cytarabine or daunorubicin.
- Review previous and cumulative anthracycline exposure, cardiac disease, mediastinal radiotherapy and concomitant cardiotoxic treatment.
- Expect profound, potentially prolonged myelosuppression with risks of serious infection and haemorrhage.
- Assess severe hepatic impairment or dialysis-dependent kidney failure individually because clinical experience is lacking.
- Consider the copper content in Wilson's disease or another copper-related disorder.
- Prevent extravasation and follow local cytotoxic handling and disposal procedures.
Contraindications and cautions
- History of serious hypersensitivity to cytarabine, daunorubicin or any excipient.
Monitoring
- Full blood count before treatment and regularly until neutrophil and platelet recovery
- Cardiac function before treatment, particularly with cardiac risk factors, and subsequently when clinically indicated
- Liver and kidney function before and periodically during treatment
- Uric acid and clinical features of tumour lysis
- Infection, bleeding, infusion reactions and extravasation
Clinical pharmacology
Cytarabine is converted intracellularly to an active nucleotide that primarily inhibits DNA synthesis. Daunorubicin intercalates with DNA, inhibits topoisomerase II and generates DNA-damaging free radicals. Liposomal co-encapsulation prolongs their circulation and delivers the fixed combination together.
Formulation and product differences
- A liposomal, fixed-combination powder requiring reconstitution and dilution before intravenous infusion
- Pharmacokinetically and clinically distinct from separately administered or non-liposomal cytarabine and daunorubicin
- Contains copper gluconate and requires caution in copper-related disorders
- For intravenous use only; intramuscular, subcutaneous and intrathecal administration are prohibited
cytarabine + daunorubicin interactions
Formal interaction studies have not been performed. The treatment team should review all prescribed, over-the-counter and complementary products.
Other cardiotoxic medicines, including anthracyclines such as doxorubicin
They may increase the risk of heart damage and require close assessment and monitoring.
Medicines that can damage or impair the liver
They may increase toxicity, so liver function may need more frequent monitoring.
Live or live-attenuated vaccines
These should be avoided because chemotherapy-related immunosuppression can permit serious infection.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.